Lannett Co (LCI) & CoLucid Pharmaceuticals (CLCD) Head-To-Head Review

Lannett Co (NYSE: LCI) and CoLucid Pharmaceuticals (NASDAQ:CLCD) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, analyst recommendations, profitability, institutional ownership and earnings.

Earnings and Valuation

This table compares Lannett Co and CoLucid Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Lannett Co $637.34 million 1.32 $245.00 million ($0.03) -753.08
CoLucid Pharmaceuticals N/A N/A N/A ($3.44) -13.53

Lannett Co has higher revenue and earnings than CoLucid Pharmaceuticals. Lannett Co is trading at a lower price-to-earnings ratio than CoLucid Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Lannett Co and CoLucid Pharmaceuticals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lannett Co 0 3 2 0 2.40
CoLucid Pharmaceuticals 0 3 1 0 2.25

Lannett Co presently has a consensus target price of $21.00, indicating a potential downside of 7.08%. CoLucid Pharmaceuticals has a consensus target price of $47.83, indicating a potential upside of 2.80%. Given CoLucid Pharmaceuticals’ higher possible upside, analysts plainly believe CoLucid Pharmaceuticals is more favorable than Lannett Co.

Volatility and Risk

Lannett Co has a beta of 2.76, suggesting that its share price is 176% more volatile than the S&P 500. Comparatively, CoLucid Pharmaceuticals has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500.


This table compares Lannett Co and CoLucid Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Lannett Co -0.09% 19.80% 6.42%
CoLucid Pharmaceuticals N/A -83.51% -70.62%

Institutional & Insider Ownership

88.0% of Lannett Co shares are held by institutional investors. Comparatively, 64.2% of CoLucid Pharmaceuticals shares are held by institutional investors. 15.0% of Lannett Co shares are held by company insiders. Comparatively, 13.7% of CoLucid Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


Lannett Co beats CoLucid Pharmaceuticals on 9 of the 11 factors compared between the two stocks.

About Lannett Co

Lannett Company, Inc. develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc. As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules. The Company has additional products under development, which are orally administered solid oral-dosage products (tablet/capsule) or oral solutions, nasal, topicals or parentarels, as well as other dosage forms.

About CoLucid Pharmaceuticals

CoLucid Pharmaceuticals, Inc. is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies. Lasmiditan, the Company’s lead product candidate, is an oral tablet for the acute treatment of migraine in adults. Lasmiditan selectively targets 5-HT1F receptors expressed in the trigeminal pathway in the central nervous system (CNS). Lasmiditan is designed to penetrate the CNS and block the pathway that contributes to headache pain. It is developing IV lasmiditan for the acute treatment of headache pain associated with migraine in adults, to be used in emergency rooms and urgent care settings. The Company is conducting its Phase III randomized, double-blind, placebo-controlled clinical trial of lasmiditan.

Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with's FREE daily email newsletter.

Leave a Reply